Damazio B, Hao Q, Arenas JD, Riley, III TR, Hollenbeak CS. Risk factors for 30-day readmission following liver transplantation in Pennsylvania. J Liver Trans. 2022 Oct;8:100114. doi: 10.1016/j.liver.2022.100114
Shakoor A, Esterberg E, Acharya NR. Recurrence of uveitis after discontinuation of infliximab. Ocul Immunol Inflamm. 2014 Apr;22(2):96-101. doi: 10.3109/09273948.2013.812222
Martel JN, Esterberg E, Nagpal A, Acharya NR. Infliximab and adalimumab for uveitis. Ocul Immunol Inflamm. 2012 Feb;20(1):18-26. doi: 10.3109/09273948.2011.633205.